TY  - GEN
AU  - Cascinu,Stefano
AU  - Rosati,Gerardo
AU  - Nasti,Guglielmo
AU  - Lonardi,Sara
AU  - Zaniboni,Alberto
AU  - Marchetti,Paolo
AU  - Leone,Francesco
AU  - Bilancia,Domenico
AU  - Iaffaioli,Rosario Vincenzo
AU  - Zagonel,Vittorina
AU  - Giordano,Monica
AU  - Corsi,Domenico C
AU  - Ferraú,Francesco
AU  - Labianca,Roberto
AU  - Ronzoni,Monica
AU  - Scartozzi,Mario
AU  - Galli,Francesca
TI  - Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
SN  - 1879-0852
PY  - 2017///0911
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - Camptothecin
KW  - Carcinoma
KW  - drug therapy
KW  - Cetuximab
KW  - Colorectal Neoplasms
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Irinotecan
KW  - Kaplan-Meier Estimate
KW  - Leucovorin
KW  - Male
KW  - Middle Aged
KW  - Organoplatinum Compounds
KW  - Oxaliplatin
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1016/j.ejca.2017.06.029
ER  -